| Filed | Form | Items | Signal | Score | Summary | Link |
|---|---|---|---|---|---|---|
| 2026-06-12 17:01 | 8-K | ["5.07"] | other | 0.00 | Routine 8-K filing of annual stockholder meeting results; no M&A signals present. | SEC · detail |
| 2026-05-27 06:40 | 8-K | ["1.01"] | material agreement | 0.15 | Revenue participation agreement with Blackstone Life Sciences for zumilokibart funding; not M&A-related. | SEC · detail |
| 2026-05-27 06:37 | 8-K | ["7.01", "8.01"] | other | 0.05 | Clinical trial results announcement for zumilokibart; no M&A signals present. | SEC · detail |
| 2026-05-11 07:10 | 8-K | ["2.02", "9.01"] | other | 0.05 | Routine quarterly earnings announcement with no M&A, activist, or strategic transaction indicators. | SEC · detail |